Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (787)	1/16/1998 10:12:00 PM
From: BulbaMan	Read Replies (2) \| Respond to of 3578

I think the significance of telomerase as a cancer diagnostic tool has been overlooked in evaluating Geron's revenue potential. And Geron's diagnostic deal with Boehringer Mannheim, announced in December, has received little notice. At H&Q., Geron CEO Ron Eastman said the diagnostic deal was done at very favorable terms to Geron (although the exact details have not been made public). Eastman also said Geron has very strong patent protection on telomerase-based diagnostics as well as for pretty much everything related to telomerase/telomere biology. A diagnostic product, of course, would take less time to bring to market than a therapeutic product.